Guangzhou BeBetter Medicine Technology | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Trial results

13 November 2023

Phase 1 entrants seek improved safety

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

Subscribe to Guangzhou BeBetter Medicine Technology